MF59佐剂H5N1大流行流感疫苗在婴幼儿及儿童中的免疫原性与安全性
这项2期随机观察者盲法多中心研究纳入420名6月龄至<9岁儿童,比较6种MF59佐剂H5N1疫苗配方(HA 1.875/3.75/7.5 μg联合标准或半量MF59)两剂接种的免疫原性与安全性。结果显示各疫苗组HI抗体滴度≥1:40比例为74.6%–90.0%,MN抗体滴度≥1:40见于所有受试者,标准MF59含量组抗体滴度更高且更持久,不良反应率组间相似,未观察到安全性信号。
要点
- 各疫苗组第二剂后3周HI抗体滴度≥1:40比例为74.6%–90.0%。
- 所有受试者MN抗体滴度≥1:40,89.6%–97.1%受试者MN≥1:160。
- 标准MF59含量组免疫应答更强更持久,且未增加反应原性。
核心结论
- 含7.5 μg HA加0.25 mL MF59的aH5N1疫苗在儿童中具有免疫原性,安全性和反应原性可接受。
研究设计与样本
- 2期、剂量范围、随机、观察者盲法、多中心研究,纳入420名6月龄至<9岁儿童,按年龄分层随机分配至6种aH5N1配方组,间隔3周接种两剂。
主要发现
- 第二剂后3周,各疫苗组HI几何平均比值范围为13.8至25.0,HI滴度≥1:40的受试者比例为74.6%至90.0%。
- 所有受试者均观察到MN滴度≥1:40,各疫苗组MN滴度≥1:160的受试者比例为89.6%至97.1%。
- 第二剂后3周和6个月时,接受标准MF59含量的组别 consistently 观察到更高滴度。
- 不良事件率在各疫苗组间相似,与抗原或佐剂含量无关,未观察到安全性信号。
- 较高的MF59含量与更强且更持久的免疫应答相关,但未增加反应原性。
关键数值与推荐
- 疫苗配方含HA 1.875、3.75或7.5 μg,联合0.25 mL MF59(标准佐剂含量)或0.125 mL MF59(半量佐剂含量)。
- 免疫原性评价采用血凝抑制(HI)和微量中和(MN)试验。
临床怎么用
- 在6月龄至<9岁儿童中,含7.5 μg HA加0.25 mL MF59的aH5N1疫苗两剂接种(间隔3周)可诱导可接受的免疫应答且安全性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zoonotic influenza pandemics can cause substantial morbidity and mortality, especially in children. The present study evaluated the immunogenicity and safety of six formulations of an MF59-adjuvanted H5N1 vaccine (aH5N1). In this phase 2, dose-ranging study, children aged 6 months to <9 years were stratified by age and randomized to one of six aH5N1 formulations containing 1.875, 3.75, or 7.5 μg HA combined with 0.25 mL MF59 (standard adjuvant content) or 0.125 mL MF59 (half adjuvant content). Vaccines were administered twice, 3 weeks apart. Immunogenicity was evaluated using hemagglutination inhibition (HI) and microneutralization (MN) assays. A total of 420 children from Europe and Asia participated in the study. Three weeks after the second vaccination, HI geometric mean ratios ranged from 13.8 to 25.0 and HI titers ≥1:40 ranged from 74.6% to 90.0% of subjects across vaccine groups. MN titers ≥1:40 were observed in all subjects, and MN titers ≥1:160 in 89.6% to 97.1% of subjects across vaccine groups. At 3 weeks and at 6 months after the second vaccination, higher titers were consistently observed in groups receiving standard MF59 content. Adverse event rates were similar across vaccine groups regardless of antigen or adjuvant content, and no safety signals were observed. Higher MF59 content was associated with a greater magnitude and persistence of immune responses but was not associated with increased reactogenicity. These data confirm that aH5N1 containing 7.5 μg HA plus 0.25 mL MF59 is immunogenic with an acceptable safety and reactogenicity profile in children.
引用
- Põder A, Trinidad-Aseron M, Van Twuijver E, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study. Vaccine. 2026. PMID: 41895156. doi:10.1016/j.vaccine.2026.128504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。